PFIZER INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America
- Conditions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 244
- Registration Number
- NCT00084227
Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer
- Conditions
- First Posted Date
- 2004-06-04
- Last Posted Date
- 2012-09-11
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00004071
- Locations
- ๐บ๐ธ
St. Vincents Comprehensive Cancer Center, New York, New York, United States
๐บ๐ธComprehensive Cancer Care Specialists of Boca Raton, Boca Raton, Florida, United States
๐บ๐ธFlorida Cancer Specialists, Fort Myers, Florida, United States
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
- First Posted Date
- 2004-06-04
- Last Posted Date
- 2010-01-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 750
- Registration Number
- NCT00083889
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Sutton Surrey, United Kingdom
SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2012-09-11
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00003293
- Locations
- ๐บ๐ธ
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2004-05-25
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00004200
- Locations
- ๐บ๐ธ
Agouron Pharmaceuticals, Inc., La Jolla, California, United States
Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa
- Conditions
- First Posted Date
- 2004-05-14
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 238
- Registration Number
- NCT00082576
- Locations
Pfizer Investigational Site
Azithromycin in Combination With Chloroquine Versus Chloroquine in the Eradication of Asymptomatic Plasmodium Falciparum
- Conditions
- First Posted Date
- 2004-05-14
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00082563
Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2004-04-19
- Last Posted Date
- 2012-09-11
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00004252
- Locations
- ๐บ๐ธ
Tower Hematology Oncology Medical Group, Los Angeles, California, United States
๐บ๐ธRaleigh Hematology/Oncology Associates - Wake Practice, Raleigh, North Carolina, United States
๐บ๐ธAPN-IMPATH Research Corporation, Fort Lee, New Jersey, United States
Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment
- Conditions
- First Posted Date
- 2004-03-02
- Last Posted Date
- 2006-11-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 56
- Registration Number
- NCT00078468
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, New York, New York, United States
A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.
- Conditions
- First Posted Date
- 2004-02-18
- Last Posted Date
- 2008-11-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64
- Registration Number
- NCT00078000
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Boston, Massachusetts, United States